Amgen (AMGN) announced that the global Phase 3 DeLLphi-304 clinical trial evaluating Imdelltra as a treatment for patients with small cell lung ...

Amgen's global Phase III DeLLphi-304 trial of Imdelltra (tarlatamab-dlle) has met its primary endpoint at a planned interim ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Amgen (NasdaqGS:AMGN) made considerable strides in its oncology portfolio, as evidenced by the successful interim results for ...

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the ...

Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy ...

US biotech giant Amgen (Nasdaq: AMGN) today announced a significant breakthrough with its global Phase III DeLLphi-304 ...

1 The topline results from DeLLphi-304 demonstrate overwhelming clinical benefit for people living with this devastating disease and affirm IMDELLTRA as standard of care," said Jay Bradner ...

April 11, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with ...